Mirum Pharmaceuticals (NASDAQ:MIRM) Given New $66.00 Price Target at HC Wainwright

Mirum Pharmaceuticals (NASDAQ:MIRM) had its target price raised by HC Wainwright from $58.00 to $66.00 in a research report report published on Monday, Benzinga reports. The firm currently has a buy rating on the stock.

A number of other analysts have also issued reports on MIRM. Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $34.00 to $39.00 and gave the stock an outperform rating in a research report on Monday. Cantor Fitzgerald reiterated an overweight rating and issued a $40.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, May 9th. Morgan Stanley reduced their target price on Mirum Pharmaceuticals from $57.00 to $53.00 and set an overweight rating on the stock in a research report on Friday, May 10th. Citigroup upped their price objective on shares of Mirum Pharmaceuticals from $37.00 to $38.00 and gave the company a buy rating in a research note on Thursday, May 9th. Finally, SVB Leerink decreased their target price on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an outperform rating on the stock in a research report on Monday, March 18th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of Buy and a consensus price target of $50.55.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM opened at $33.00 on Monday. The company has a quick ratio of 3.47, a current ratio of 3.68 and a debt-to-equity ratio of 1.31. Mirum Pharmaceuticals has a fifty-two week low of $23.14 and a fifty-two week high of $35.56. The business has a fifty day moving average of $25.26 and a 200-day moving average of $27.25. The stock has a market cap of $1.56 billion, a price-to-earnings ratio of -8.89 and a beta of 1.10.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, May 8th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.14). The firm had revenue of $69.22 million during the quarter, compared to analyst estimates of $69.71 million. Mirum Pharmaceuticals had a negative net margin of 69.67% and a negative return on equity of 56.46%. As a group, analysts predict that Mirum Pharmaceuticals will post -1.39 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Eric Bjerkholt acquired 2,000 shares of Mirum Pharmaceuticals stock in a transaction on Wednesday, March 27th. The shares were bought at an average price of $24.80 per share, for a total transaction of $49,600.00. Following the completion of the purchase, the chief financial officer now directly owns 14,000 shares in the company, valued at approximately $347,200. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Saira Ramasastry sold 5,000 shares of the firm’s stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $25.68, for a total transaction of $128,400.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Eric Bjerkholt acquired 2,000 shares of the business’s stock in a transaction on Wednesday, March 27th. The stock was purchased at an average price of $24.80 per share, for a total transaction of $49,600.00. Following the acquisition, the chief financial officer now directly owns 14,000 shares in the company, valued at $347,200. The disclosure for this purchase can be found here. Insiders own 22.87% of the company’s stock.

Institutional Trading of Mirum Pharmaceuticals

Large investors have recently modified their holdings of the business. Swiss National Bank boosted its stake in shares of Mirum Pharmaceuticals by 1.3% during the 3rd quarter. Swiss National Bank now owns 54,400 shares of the company’s stock valued at $1,719,000 after buying an additional 700 shares during the last quarter. Janney Montgomery Scott LLC boosted its stake in Mirum Pharmaceuticals by 5.3% during the 3rd quarter. Janney Montgomery Scott LLC now owns 18,925 shares of the company’s stock valued at $598,000 after acquiring an additional 950 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Mirum Pharmaceuticals by 210.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 224,571 shares of the company’s stock worth $7,096,000 after acquiring an additional 152,287 shares in the last quarter. State Board of Administration of Florida Retirement System bought a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter worth about $251,000. Finally, Citigroup Inc. raised its stake in shares of Mirum Pharmaceuticals by 43.9% in the 3rd quarter. Citigroup Inc. now owns 58,723 shares of the company’s stock valued at $1,856,000 after purchasing an additional 17,917 shares in the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.